144TiPOPEN-LABEL SINGLE-ARM PHASE IV STUDY TO ASSESS THE EFFICACY AND SAFETY OF AFATINIB AS SECOND-LINE THERAPY FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBOURING COMMON EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS (DEL19 AND/OR L858R) WHO HAVE FAILED FIRST-LINE TREATMENT WITH PLATINUM-BASED CHEMOTHERAPY


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles